Company profile for Mira Pharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Mira Pharmaceuticals Inc is an early pre-clinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic THC analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. MIRA1a is being developed as the first prescription drug to target the CB1 and CB2 receptors for chronic pain and anxiety w...
Mira Pharmaceuticals Inc is an early pre-clinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic THC analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. MIRA1a is being developed as the first prescription drug to target the CB1 and CB2 receptors for chronic pain and anxiety without the impurities of marijuana or its side effects, such as increased appetite and paranoia.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
855 N Wolfe St, Ste 601.2
Telephone
Telephone
+1 8138642562
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.indianpharmapost.com/clinical-trials/mira-pharmaceuticals-advances-oral-ketamir-2-into-phase-1-mad-study-for-chemotherapy-induced-neuropathic-pain-18091

INDPHARMAPOST
29 Oct 2025

https://www.pharmiweb.com/press-release/2025-10-24/mira-pharmaceuticals-initiates-multiple-ascending-dose-mad-phase-1-study-of-oral-ketamir-2-and-sel

PHARMIWEB
24 Oct 2025

https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/mira-pharmaceuticals-closes-acquisition-of-skny-pharmaceuticals-expan-1079783

ACCESSWIRE
30 Sep 2025

https://www.pharmiweb.com/press-release/2025-09-22/mira-pharmaceuticals-announces-favorable-topline-results-from-phase-1-sad-study-of-oral-ketamir-2-a

PHARMAWEB
22 Sep 2025

https://www.pharmiweb.com/press-release/2025-09-16/mira-pharmaceuticals-reports-positive-ptsd-data-demonstrating-ketamir-2-restores-normalized-behavior

PHARMAWEB
16 Sep 2025

https://www.pharmiweb.com/press-release/2025-09-12/mira-pharmaceuticals-shareholders-approve-acquisition-of-skny-pharmaceuticals-advancing-next-genera

PHARMAWEB
12 Sep 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty